Comparative Study of Different Doses of Mg as a Protective Agent in Nephrotoxicity in Patients With H and N Cancer

• Status: Enrolling by invitation
• Trial end date: 2024-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this [ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.] In 75 participant population with head and neck cancer recieved cisplatin it aims to answer are: • • optimal doses of magnesium as 3 groups each group take 1gm of magnesium then second group take 2gm of magnesium and finally third group take 3gm of magnesium Researchers will compare [ 3 groups ] to see if [ magnesium has effects in prevention cisplatin nephrotoxicity].

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tanta University
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• diagnosed with head and neck cancer recieved cisplatin ECOG <2 eGFR>59 ml/min/1.73 Adequate hematological parameters

Exclusion Criteria:

• pregnant and lactating women Using of nephrotoxic drugs as NSAIDs Patients with hypersensitivity to any drug used Diabetic patients Patients with cardiovascular diseases